NRAS and melanoma: Approximately 40%–50% of melanoma patients have activating mutations in BRAF at valine 600 (90% are BRAFV600E) and another 15%–25% have mutations in the neuroblastoma RAS viral oncogene homolog (NRAS), and either alteration results in constitutive activation of the MAPK pathway [156].